U.S. Bioscience lodenosine

Executive Summary

Interim 12-week Phase II data show 55% of patients receiving lodenosine as part of a triple combination therapy experienced a reduction in HIV-RNA levels below 50 copies/mL vs. 50% of patients randomized to receive 3TC after 12 weeks of therapy. All patients were given d4T and indinavir (Merck's Crixivan). No adverse events reported have been attributed to lodenosine. The percentage of patients who have discontinued the study is 7.1% (lodenosine 100 mg), 10% (lodenosine 200 mg), 13.3% (lodenosine 300 mg) and 21.1% (control). Results from 24-week evaluations are anticipated next year, U.S. Bioscience said. U.S. Bioscience is in the process of being acquired by MedImmune (1"The Pink Sheet" Sept. 27, p. 21)